Buspirone attenuates tolerance to analgesic effect of morphine in mice with skin cancer

Pakistan Journal of Pharmaceutical Sciences

Volumn 23, Issue 2, 2010, Pages 201-206

  Nayebi, Alireza Mohajjel ^a   Rezazadeh, Hassan ^b   Nourafkan, Mostafa ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Buspirone; Morphine; Skin cancer; Tolerance

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANALGESIC AGENT; BUSPIRONE; CROTON OIL; MORPHINE;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PAIN; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HOT PLATE TEST; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PAIN THRESHOLD; SKIN CANCER; SKIN TUMOR;

ANALGESICS; ANIMALS; BENZ(A)ANTHRACENES; BUSPIRONE; CROTON OIL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG PARTIAL AGONISM; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; MICE; MORPHINE; RECEPTOR, SEROTONIN, 5-HT1A; SKIN NEOPLASMS;

EID: 77951715857     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Abdel-Zaher AO, Hamdy MM, Aly SA, Abdel-Hady RH and Abdel-Rahman S (2006). Attenuation of morphine tolerance and dependence by aminoguanidine in mice. Eur. J. Pharmacol., 540: 60-66. (Pubitemid 43866689)
2. Arends RH, Hayashi TG, Luger TJ and Shen DD (1998). Co-treatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats. J. Phamacol. Exp. Ther., 286: 585-592.
3. Ashman LK, Murray AW, Cook MG and Kotlarski I (1982). Two-stage skin carcinogenesis in sensitive and resistant mouse strains. Carcinogenesis, 3: 99-102. (Pubitemid 12112772)
4. Bruins Slot LA, Koek W, Tarayre JP and Colpaert FC (2003). Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel central analgesic, F 13640. Eur. J. Pharmacol., 466: 271-279. (Pubitemid 36416614)
5. Bryant CD, Eitan S, Sinchak K, Fanselow MS and Evans CJ(2006). NMDA receptor antagonism disrupts the development of morphine analgesic tolerance in male, but not female C57BL/6J mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 291: R315-26. (Pubitemid 44035637)
6. 1A receptor agonist, F 13640 induces c-Fos protein expression in spinal cord dorsal horn neurons. Brain Res., 974: 212-221.
7. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, Brummett C and Mao J (2008). The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg. Anesth. Pain Med., 33: 199-206. (Pubitemid 351539079)
8. Colpaert FC, Deseure K, Stinus L and Adriaensen H (2006). High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and effective conditioning. J. Pharmacol. Exp. Ther., 316: 892-893. (Pubitemid 43131019)
9. Colpaert FC, Tarayre JP, Koek W, Pauwels PJ, Bardin L, XU XJ, Wiesenfeld-Hallin Z, Cosi C, Carilla-Durand E, Assiě MB, Vacher B (2002). Large-amplitude 5-HT1A receptor activation: a new mechanism of profound central analgesia. Neuropharmacology, 43: 945-958. (Pubitemid 35341231)
10. Colpaert FC (2006). 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr. Opin. Investig. Drugs, 7: 40-47.
11. Danysz W, Kozela E, Parsons CG, Sladek M, Bauer T and Popik P (2005). Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance. Neuropharmacology, 48: 360-371. (Pubitemid 40249999)
12. 1A agonist (3-chloro-4-flourophenyl)-[ 4-fluoro-4-{[5-methyl-pyridin-2-ylmethyl)-amino]- methyl}piperidin-1-yl]-methadon (F 13640) attenuates allodynia-like behavior in a rat model of trigeminal neuropathic pain. J. Pharmacol. Exp. Ther., 306: 505-514.
13. Deseure KR, Adriaensen HF and Colpaert FC (2004). Effects of the combined continuous administration of morphine and the high-efficacy 5-HT1A agonist, F 13640 in a rat model of trigeminal neuropathic pain. Eur. J. Pain, 8: 547-554.
14. Drouin C, Blanc G, Trovero F, Glowinski J and Tassin JP (2001): Cortical αI-adrenergic regulation of acute and sensitized morphine locomotor effects. Neuroreport, 12: 3483-3486. (Pubitemid 33065483)
15. Dyuizen IV, Deridovich II, Kurbatskii RA and Shorin VV (2004). No-ergic neurons of the cervical nucleus of the rat brain in normal conditions and after administration of opiates. Neurosci. Behav. Physiol., 34: 621-626.
16. Eriksen JL and Druse MJ (2001). Potential involvement of S100B in the protective effects of a serotonin-1a agonist on ethanol-treated astrocytes. Dev. Brain Res., 128: 157-164.
17. Fang LH, Zhang YH and Ku BS (2005). Fangchinoline inhibited the antinociceptive effect of morphine in mice. Phytomedicine, 12: 183-188. (Pubitemid 40348618)
18. Fortier MA, Krishnaswamy K, Danyod G, Boucher-Kovalik S and Chapdalaine P (2008). A postgenomic integrated view of prostaglandins in reproduction: implication of other body systems. Curr. Med. Chem., 15: 2866-2875.
19. Giordano J and Rogers L (1992). Putative mechanisms of buspirone-induced antinociception in the rat. Pain, 50: 365-372.
20. Gower AJ and Tricklebank MD (1988): Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonfilict test in the rat. Eur. J. Pharmacol., 155: 129-137.
21. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V and Expert Working Group of the Research Network of the European Association for Palliative Care (2001). Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer, 84: 587-593.
22. Jadhav SA, Gaikwad RV, Gaonkar RK, Thorat VM, Gursale SC and Balsara JJ (2008). Dose-dependent response of central dopaminergic systems to buspirone in mice. Indian J. Exp. Biol., 46: 704-714.
23. Jolas T and Aghajanian GK (1997). Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in vitro. Brain Res., 755: 229-245.
24. Jolas T, Nestler EJ and Aghajanian GK (2000). Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience, 95: 433-443.
25. Liu W, Wang CH, Cui Y, Mo LQ, Zhi JL, Sun SN, Wang YL, Yu HM, Zhao CM, Feng JQ and Chen PX (2006). Inhibition of neuronal nitric oxide synthase antagonizes morphine antinociceptive tolerance by decreasing activation of p38 MAPK in the spinal microglia. Neurosci. Lett., 410: 174-177. (Pubitemid 44750337)
26. Mandalà M, Moro C, Labianca R, Cremonesi M and Barni S (2006). Optimizing use of opiates in the management of cancer pain. Ther. Clin. Risk Manag., 2: 447-453.
27. Mendez IA and Trujillo KA (2008). NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology, 196: 497-509.
28. Narita M, Suzuki M, Narita M, Yajima Y, Suzuki R, Shioda S and Suzuki T (2004). Neuronal protein kinase C gamma-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine. Eur. J. Neurosci., 19: 479-484. (Pubitemid 38177887)
29. Nayebi ARM and Charkhpour M (2006): Role of 5-HT1A and 5-HT2 receptors of dorsal and median raphe nucleus in tolerance to morphine analgesia in rats. Pharmacol. Biochem. Behav., 83: 203-207.
30. Nayebi MA, Rezazadeh H and Parsa Y (2009): Effect of fluoxetine on tolerance to analgesic effect of morphine in mice with skin cancer. Pharmacol. Rep., 61: 453-458.
31. Nemmani KV and Mogil JS (2003). Serotonin-GABA interactions in the modulation of mu- and kappa-opioid analgesia. Neuropharmacology, 44: 304-310.
32. O'Connell JF, Klein-Szanto AJ, DiGiovanni DM, Fries JW and Slaga TJ (1986). Enhanced malignant progression of mouse skin tumors by the free-radical generator benzoyl peroxide. Cancer Res., 46: 2863-2865.
33. Rezazadeh H, Nayebi AR, Garjani A, Sheikhulislami A and Babaei H (2005). Evidence that iron overload plus croton oil induce skin tumours in mice. Hum. Exp. Toxicol., 24: 409-413. (Pubitemid 41206348)
34. Santamarta MT, Ulibarri I and Pineda J (2005). Inhibition of neuronal nitric oxide synthase attenuates the development of morphine tolerance in rats. Synapse, 57: 38-46. (Pubitemid 40756333)
35. Scháfers M and Sorkin L. Effect of cytokines on neuronal excitability. Neurosci. Lett., 437: 188-193.
36. Sellick SM and Crooks DL (1999). Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development forsychologicalinterventions. Psychooncology, 8: 315-333.
37. Sindrup SH and Jensen TS (1999). Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain, 83: 389-400.
38. Song P and Zhao ZQ (2001). The involvement of glial cells in the development of morphine tolerance. Neurosci. Res., 39: 281-286.
39. Tajuddin NF, Luisa AO, Eriksen JL and Druse MJ (2003). Effects of ethanol and ipsapirone on the development of midline raphe glial cells and astrocytes. Alcohol, 29: 157-164.
40. Trujillo KA and Akil H (1995): Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Depend., 38: 139-154.
41. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S and Inoue K (2004). Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia, 45: 89-95. (Pubitemid 38076231)
42. Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ and Wilcox GL (2003). Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain, 101: 175-186.
43. Woolf CJ and Salter MW (2000). Neuronal plasticity: increasing the gain in pain. Science, 288: 1765-1769.
44. Xiao DQ, Zhu JX, Tang JS and Jia H (2005). 5-hydroxytryptamine 1A (5-HT1A) but not 5-HT3 receptor is involved in mediating the nucleus submedius 5-HT-evoked antinociception in the rat. Brain Res., 1046: 38-44.
45. Xu T, Jiang W, Du D, Xu Y, Hu Q and Shen Q (2007). Role of spinal metabotropic glutamate receptor subtype 5 in the development of tolerance to morphine-induced antinociception in rat. Neurosci. Lett., 420: 155-159. (Pubitemid 46818676)
46. Xu T, Jiang W, Du D, Xu Y, Zhou Q, Pan X, Lou Y, Xu L and Ma K (2008). Inhibition of MPEP on the development of morphine antinociceptive tolerance and the biosynthesis of neuronal nitric oxide synthase in rat spinal cord. Neurosci. Lett., 436: 214-218.
47. 1A receptor-mediated inverse tolerance. Trends Pharmacol. Sci., 24: 634-639.